This is intended for HCPs practising in Great Britain (England, Scotland and Wales) only.


VAXELIS (DTaP/IPV/Hib/Hep B) is a hexavalent vaccine indicated for primary and booster vaccination in infants and toddlers from the age of 6 weeks, against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive disease caused by Haemophilus influenzae type b (Hib).1

VAXELIS contains 5 acellular pertussis components with an aim to effectively elicit seroprotection when used in a series of primary vaccinations. The Hib PRP-OMPC conjugate used in VAXELIS elicits earlier Hib antibody responses than PRP conjugated to tetanus toxoid.2,3

VAXELIS is a fully liquid hexavalent vaccine with a Luer-lock syringe, helping to reduce preparation time and potentially preparation errors.1,4-6

Before you prescribe this vaccine please refer to the Prescribing Information and SmPC.


VAXELIS is used in the UK National Immunisation Programme at 8, 12 and 16 weeks old and is available to order via Immform. Any enquiries on vaccine availability can be directed to UKHSA'

VAXELIS is the result of a U.S.-based joint-partnership established in 1991 between Merck & Co, Inc and Sanofi and draws upon both companies' experience in the development, manufacturing and marketing of individual and combination vaccines.


0.5 mL suspension for injection in pre-filled syringe.


Primary schedule: Two or three doses with at least one month between doses. Primary vaccination schedule should be given in accordance with the official recommendations.

Booster: After two-dose or three-dose primary series, a booster should be given at least six months after the last priming dose. Booster dose should be given in accordance with the official recommendations. As a minimum, a dose of Hib vaccine must be administered.

Age range

May be given from 6 weeks of age

VAXELIS can be given concomitantly with:1

  • Pneumococcal polysaccharide vaccines*
  • Rotavirus vaccines
  • Measles, mumps, rubella, and varicella-containing (MMRV) vaccines
  • Meningococcal C vaccines in infants

* Clinical data indicate that when VAXELIS is co-administered with pneumococcal conjugate vaccine (PCV13), the rate of fever is higher following the booster dose in the second year of life compared to the primary series; almost all fevers were mild or moderate and transient.1

Before you prescribe this vaccine, please refer to the Prescribing Information and Summary of Product Characteristics.

Useful Resources:

VAXELIS can give you ease and convenience

VAXELIS is fully liquid and comes ready-to-use in a pre-filled syringe, simplifying administration, reducing preparation time and potentially errors.1,2

Luer-lock syringe is designed to secure the connection to the needle and prevent leakage.

Shelf life of 4 years when stored at 2°C-8°C, the longest CURRENTLY AVAILABLE hexavalent vaccine.1,4 Stable at temperatures up to 25°C for 9.5 days (228 hours).1 This can lead to less wastage during shipment and storage due to temperature excursions.

*The comparator group received DTPa3-HBV-IPV/Hib

Ways to order

You can order VAXELIS Vaccines through IMMFORM. Read more about ordering vaccines. 

    1. VAXELIS SmPC.
    2. Lee AW, Jordanov E, Boisnard F, Marshall GS. DTaP5-IPV-Hib-HepB, a hexavalent vaccine for infants and toddlers. Expert Rev Vaccines. 2017 Feb;16(2):85-92. doi: 10.1080/14760584.2017.1268920. Epub 2016 Dec 20. PMID: 27996332.
    3. Greenberg DP, Doemland M, Bettinger JA, et al. Epidemiology of pertussis and haemophilus influenzae type b disease in Canada with exclusive use of diphtheria-tetanus-acellular pertussis inactivated poliovirus-haemophilus influenzae type b pediatric combination vaccine and an adolescent-adult tetanus-diphtheria-acellular pertussis vaccine: implications for disease prevention in the United States. Pediatr Infect Dis J. 2009;28(6):521-528
    4. Infanrix hexa SmPC.
    5. De Coster I, Fournie X, Faure C, et al. Assessment of preparation time with fully-liquid versus non-fully liquid paediatric hexavalent vaccines. A time and motion study. Vaccine. 2015:33(32):3976-3982
    6. European Medicines Agency: Assessment report Vaxelis. human/EPAR/vaxelis (Accessed May 2023).

MAT-XU-2301124 (v1.0)
Date of preparation: May 2023